Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001 Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

EVA ERZSEBET SZEGEZDI

Research output: Chapter in Book or Conference Publication/Proceeding › Conference Publication › peer-review

Original languageEnglish (Ireland)
Title of host publicationAmerican Society of Hematology
Place of Publication10.1182/blood-2021-145530
Publication statusPublished - 1 Dec 2021

Authors (Note for portal: view the doc link for the full list of authors)

  • Authors
  • Swan D, O'Dwyer ME,Cahill M, Krawczyk, Mykytiv JV, Quinn J, Henderson R, McEllistrim C, Hernando A, Parker I, Nolan M, Lenihan E, Szegezdi E,Naicker SD, Lynch K, Natoni A, Ryan AE, Murphy P,
  • Swan D, ODwyer ME,Cahill M, Krawczyk, Mykytiv JV, Quinn J, Henderson R, McEllistrim C, Hernando A, Parker I, Nolan M, Lenihan E, Szegezdi E,Naicker SD, Lynch K, Natoni A, Ryan AE, Murphy P,

Cite this